CSIMarket


Plus Therapeutics Inc   (PSTV)
Other Ticker:  
 


 

Plus Therapeutics Inc

PSTV's Financial Statements and Analysis



Plus Therapeutics Inc increased third quarter of 2023 net loss per share of $-1.00 compare to net loss per share of $-0.19 recorded in the same quarter a year ago a decrease compare to $-0.59 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -1 $  1 Mill
$-0.81     $+1M     +1598.63 %



Plus Therapeutics Inc 's Revenue rose by 1598.63 % in third quarter of 2023 (Sep 30 2023) year on year, to $1 million and declined by -33.12 % sequentially.


Plus Therapeutics Inc is

More on PSTV's Income Statement



Plus Therapeutics Inc in the third quarter of 2023 recorded net loss of $-3.219 million, an improvement compare to net loss of $-5.219 million in III. Quarter a year ago.

Sequentially net loss advanced

More on PSTV's Growth

Plus Therapeutics Inc Inventories
PSTV's Cash flow In the third quarter of 2023 company's net cash flow was $0 million, capital expenditures grew by -0.033-69.70%, to $0 millions compare to same quarter a year ago

More on PSTV's Cash flow Statement


Plus Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Plus Therapeutics Inc payed $ -4.09 cash per share, on a free-cash flow basis .

Book value fell by -23.37 % sequentially to $0.81 per share, -13.41% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.68 per share from $ 0.89.

Company issued 0.72 million shares or 28.53 % in Sep 30 2023.


More on PSTV's Dividends

 Market Capitalization (Millions) 7
 Shares Outstanding (Millions) 3
 Total Debt (Millions $) 4
 Revenue (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Plus Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Plus Therapeutics Inc had negative $ -4.09 cash flow per share, on a free-cash flow basis .

Book value fell by -23.37 % sequentially to $0.81 per share, -13.41% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.68 per share from $ 0.89.

Company issued 0.72 million shares or 28.53 % in Sep 30 2023.


More on PSTV's Balance Sheets

 Market Capitalization (Millions) 7
 Shares Outstanding (Millions) 3
 Total Debt (Millions $) 4
 Revenue (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Plus Therapeutics Inc Earnings

Phenomenal Growth: Plus Therapeutics Inc. Witnesses Spectacular 1598.63% Surge in Revenue in Q3 2023

Article: Plus Therapeutics Inc's Robust Revenue Growth Outpaces Industry Peers
Plus Therapeutics Inc has reported impressive financial results for the third quarter of 2023, with a significant revenue advance of 1598.63% year on year to $1.24 million. However, the company also experienced a shortfall per share of $-1.00. This robust revenue growth outperformed most companies in the Medical Equipment and Supplies sector, which only saw a revenue advance of 0.77% in the same period compared to the third quarter of 2022.
In contrast to the substantial revenue growth, Plus Therapeutics Inc also saw an increased shortfall from $-0.59 per share in the previous reporting period, as well as a significant dec...

Plus Therapeutics Inc Reports Impressive Revenue of $1.854 Million, Achieves Remarkable Decrease in Deficit - Growth and Financial Success Continues in Q2 2023!

Financial News Report: Plus Therapeutics Inc Reports Positive Revenue and Decreased Deficit in Q2 2023; Stock Performance Remains Strong
Plus Therapeutics Inc, a prominent Medical Equipment and Supplies company, has recently disclosed its financial results for the April to June 30, 2023 financial timeframe. The company reported $1.854 million in revenue during this period, showcasing positive growth in comparison to the corresponding reporting period last year.
Notably, Plus Therapeutics Inc achieved a significant milestone by improving its financial position. In the April to June 30, 2023 reporting period, the company reported a net deficit of $-1.482 million, marking a notable decrease from the def...